Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, Jinan 250012, China.
Department of Virology II, National Institute of Infectious Diseases, Tokyo 163-8001, Japan.
Molecules. 2022 Sep 14;27(18):5987. doi: 10.3390/molecules27185987.
Hepatitis B virus (HBV) capsid protein (Cp) is necessary for viral replication and the maintenance of viral persistence, having become an attractive target of anti-HBV drugs. To improve the water solubility of HBV capsid protein allosteric modulator (CpAM) NVR 3-778, a series of novel carboxylic acid and phosphate prodrugs were designed and synthesized using a prodrug strategy. In vitro HBV replication assay showed that these prodrugs maintained favorable antiviral potency (EC50 = 0.28−0.42 µM), which was comparable to that of NVR 3-778 (EC50 = 0.38 µM). More importantly, the cytotoxicity of prodrug N8 (CC50 > 256 µM) was significantly reduced compared to NVR 3-778 (CC50 = 13.65 ± 0.21 µM). In addition, the water solubility of prodrug N6 was hundreds of times better than that of NVR 3-778 in three phosphate buffers with various pH levels (2.0, 7.0, 7.4). In addition, N6 demonstrated excellent plasma and blood stability in vitro and good pharmacokinetic properties in rats. Finally, the hemisuccinate prodrug N6 significantly improved the candidate drug NVR 3-778’s water solubility and increased metabolic stability while maintaining its antiviral efficacy.
乙型肝炎病毒 (HBV) 衣壳蛋白 (Cp) 是病毒复制和维持病毒持续存在所必需的,已成为抗 HBV 药物的一个有吸引力的靶点。为了提高 HBV 衣壳蛋白别构调节剂 (CpAM) NVR 3-778 的水溶性,采用前药策略设计并合成了一系列新型羧酸和磷酸前药。体外 HBV 复制实验表明,这些前药保持了良好的抗病毒活性 (EC50 = 0.28-0.42 µM),与 NVR 3-778 的抗病毒活性相当 (EC50 = 0.38 µM)。更重要的是,前药 N8 的细胞毒性 (CC50 > 256 µM) 与 NVR 3-778 (CC50 = 13.65 ± 0.21 µM) 相比显著降低。此外,在三种具有不同 pH 值 (2.0、7.0、7.4) 的磷酸盐缓冲液中,前药 N6 的水溶性比 NVR 3-778 提高了数百倍。此外,N6 在体外具有良好的血浆和血液稳定性和良好的大鼠药代动力学性质。最后,琥珀酸半酯前药 N6 显著提高了候选药物 NVR 3-778 的水溶性和代谢稳定性,同时保持了其抗病毒功效。